An observational study in Colorectal Neoplasms, sponsored by Bayer. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-15.
Sponsored by Bayer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Colorectal Neoplasms by Bayer — 2 open to participants now, 2 under way, none of them phase 3. Colorectal Neoplasms · Bayer.
Among the 32 studies in Colorectal Neoplasms by Bayer, this one is the 15th largest by enrollment of the 16 observational ones that give a count, is one of 3 that started in 2018, is one of 16 observational ones, and was the 18th registered.
6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →2 of the 32 studies in Colorectal Neoplasms by Bayer are open now, in 12 countries. Recruiting first, the newest first:
Bayer · Sites in United States, Australia, Canada and 8 more countries
Ages 18+
Vividion Therapeutics, Inc. · Sites in United States, Australia, Belgium and 8 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is below the median of 250 across 1,442 observational studies indexed under Colorectal Neoplasms.
Median enrollment 100 across the 15 interventional studies, 651 across the 16 observational. Of the 29 that completed or were terminated, 6 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
1 of the studies in Colorectal Neoplasms by Bayer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06004245Vividion Therapeutics, Inc.A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Colorectal Neoplasms by Bayer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this local NIS(Non-Interventional Study) is to determine the proportion of Belgian patients with a duration of treatment(DoT) to Stivarga of 4 months or more in relation to the total population of Belgian metastatic colorectal cancer(mCRC) patients who were treated with Stivarga between the 1st of July 2015 and 31 July 2017. In addition, this study aims to describe the clinical characteristics of Belgian patients with a short- or long-term DoT to Stivarga.
Belgian mCRC patients who were treated with Stivarga between the 1st of July 2015 and 31 July 2017.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DoT \< 4 months
Drug: Regorafenib (Stivarga, BAY73-4506)
4 months ≤ DoT \< 12 months
Drug: Regorafenib (Stivarga, BAY73-4506)
DoT ≥ 12 months
Drug: Regorafenib (Stivarga, BAY73-4506)
Antineoplastic agents, protein kinase inhibitor (L01XE21)
Proportion of patients with a DoT to Stivarga of more than 4 months versus total study sample
Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017
ECOG performance status (0, 1)
ECOG: Eastern Cooperative Oncology Group
Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017
Primary site of disease
Rectum, Left-sided colon, Right-sided colon, Colon and rectum, Transverse, Unknown (in colon)
Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017
Tumor resection (yes, no, unknown)
Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017
Specific site of metastasis
Lung, Liver, Bone, Extraregional nodes, Peritoneum, Multiple, Unknown
Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017
KRAS mutation (yes, no, unknown)
Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017
RAS mutation (yes, no, unknown)
Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017
BRAF mutation (yes, no, unknown)
Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017
Start date of Stivarga treatment
Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017
Number of prior treatment lines for metastatic cancer larger than 3 (yes, no, unknown)
Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017
Reason for discontinuation of Stivarga treatment
progression - symptomatic, Progression - radiological, Progression - radiological + symptomatic, Progression - unknown, Intolerability, Death, other, unknown, not applicable
Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017
Subsequent mCRC treatment
Chemotherapy IV, Chemotherapy oral, Biologic therapy, Chemotherapy + biologic therapy, BSC, Other, Unknown, Not applicable
Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017
Last daily Stivarga dose
80 mg, 120 mg, 160 mg, other, unknown
Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017
Duration of treatment (months)
Time frame: Retrospective chart review from 1-Jul-2015 to 1-Dec-2017
Ran from Jan 2018 to primary completion in May 2018, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.